Title: A Study Evaluating the Efficacy and Safety of Etrasimod in the Treatment of Patients With Moderately to Severely Active Crohn’s Disease (CULTIVATE)
Associated condition: Crohn’s disease
Status: Currently enrolling
Brief summary: This is a Phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel group study that seeks to evaluate the efficacy and safety of oral etrasimod as induction therapy in 225 participants with moderately to severely active Crohn’s Disease. Participants in the experimental arm of the study will receive etrasimod (APD334) tablet taken orally once daily; those in the placebo arm of the study will receive a matching placebo tablet taken by mouth, once a day.
Primary objectives: To evaluate the safety and efficacy of etrasimod in subjects with moderately to severely active Crohn’s disease.
Estimated length of study: Estimated Study Completion Date of August 2021
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
